Prognostic factor analysis for elderly patients treated for metastatic colorectal cancer in the randomized phase II trial PRODIGE 20

Annals of Oncology ◽

10.1093/annonc/mdw370.131 ◽

2016 ◽

Vol 27 ◽

pp. vi194

Author(s):

T. Aparicio ◽

O. Bouché ◽

E. Francois ◽

E. Maillard ◽

S. Kirscher ◽

...

Keyword(s):

Colorectal Cancer ◽

Factor Analysis ◽

Prognostic Factor ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.3541 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 3541-3541 ◽

Author(s):

Thomas Aparicio ◽

Olivier Bouche ◽

Eric Francois ◽

Emilie Maillard ◽

Sylvie Kirscher ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Download Full-text

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

Annals of Oncology ◽

10.1093/annonc/mdx529 ◽

2018 ◽

Vol 29 (1) ◽

pp. 133-138 ◽

Author(s):

T. Aparicio ◽

O. Bouché ◽

J. Taieb ◽

E. Maillard ◽

S. Kirscher ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii ◽

Download Full-text

Corrections to “Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results”

Annals of Oncology ◽

10.1093/annonc/mdx808 ◽

2018 ◽

Vol 29 (11) ◽

pp. 2270 ◽

Author(s):

T. Aparicio ◽

O. Bouché ◽

J. Taieb ◽

E. Maillard ◽

S. Kirscher ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii ◽

Download Full-text

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)

Annals of Oncology ◽

10.1093/annonc/mdx393.055 ◽

2017 ◽

Vol 28 ◽

pp. v179

Author(s):

E. Samalin ◽

H. Senellart ◽

S. Thezenas ◽

S. Jacquot ◽

S. Ellis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii

Download Full-text

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Abstract 373: Circulating endothelial cell measurement allows early prediction of outcome in patients with metastatic colorectal cancer treated with first-line bevacizumab and chemotherapy. Findings from the FNCLCC ACCORD 13/0503 randomized phase II trial

10.1158/1538-7445.am10-373 ◽

2010 ◽

Author(s):

Valerie Boige ◽

Jean Mendiboure ◽

Antoine Adenis ◽

Evelyne Boucher ◽

Jean-Yves Pierga ◽

...

Keyword(s):

Colorectal Cancer ◽

Endothelial Cell ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Early Prediction ◽

Prediction Of Outcome ◽

Randomized Phase Ii ◽

Cell Measurement

Download Full-text

Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)

Annals of Oncology ◽

10.1093/annonc/mdy281.154 ◽

2018 ◽

Vol 29 ◽

pp. viii202

Author(s):

A. De Stefano ◽

G. Nasti ◽

A. Febbraro ◽

G. Rosati ◽

F. Giuliani ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text